Business
Vanda Pharmaceuticals Comments on Court Ruling
WASHINGTON, Jan. 31, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) makes the following statement regarding U.S. District Court case
About this update from Vanda Pharmaceuticals Inc.
[{"type":"text","content":"WASHINGTON, Jan. 31, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) makes the following statement regarding U.S. District Court case 19-cv-30; U.S. Food and Drug Administration (FDA) v. Vanda, in which the U.S. District Court for the District of Columbia ruled in favor of the FDA:\n\"Vanda is currently reviewing the U.S. District Court's decision. Following a comprehensive review, we will determine the appropriate next steps.\"\nAbout Vanda Pharmaceuticals Inc.\nVanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com\nCorporate Contact:AJ Jones IIChief Corporate Affairs and Communications OfficerVanda Pharmaceuticals Inc.202-734-3400 [email protected] \nElizabeth Van EveryHead of Corporate AffairsVanda Pharmaceuticals Inc.202-734-3400 [email protected] \n View original content:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-comments-on-court-ruling-300997186.html\nSOURCE Vanda Pharmaceuticals Inc.","length":2529,"tagName":"div"}]